Curated News
By: NewsRamp Editorial Staff
August 05, 2025
EnPlusOne Biosciences CEO Clare Murray Ph.D. Pioneers Enzymatic RNA Synthesis
TLDR
- EnPlusOne Biosciences, led by CEO Clare Murray Ph.D., offers a competitive edge in RNA therapeutics with its enzymatic synthesis technology, enabling scalable and pure RNA production for groundbreaking treatments.
- EnPlusOne Biosciences utilizes enzymatic synthesis to produce RNA, a method that ensures high purity and scalability, addressing current manufacturing limitations and environmental concerns in RNA therapeutics.
- EnPlusOne Biosciences' mission to synthesize pure RNA at scale promises to revolutionize treatments for chronic diseases, making advanced genetic medicines accessible to patients worldwide.
- EnPlusOne Biosciences is pioneering enzymatic RNA synthesis, merging biology and chemistry to unlock new therapeutic possibilities, inspired by nature's own methods of RNA creation.
Impact - Why it Matters
The advancements in RNA synthesis technology by EnPlusOne Biosciences under the leadership of Clare Murray Ph.D. are set to transform the RNA therapeutics market. By addressing the critical challenges of scale, purity, and environmental sustainability in RNA manufacturing, EnPlusOne's enzymatic approach not only facilitates the development of current RNA-based treatments but also paves the way for future innovations. This breakthrough is crucial for meeting the growing demand for RNA therapeutics in treating chronic diseases, ensuring that these life-saving medicines can reach a wider patient population efficiently and sustainably.
Summary
Clare Murray Ph.D., a seasoned leader in the biotechnology sector, has taken the helm as CEO of EnPlusOne Biosciences, a pioneering firm based in Watertown, MA, dedicated to revolutionizing RNA synthesis through enzymatic processes. With a rich background that includes co-founding Life Edit Therapeutics and roles at ElevateBio, AgBiome, and Novartis, Dr. Murray brings a wealth of experience to EnPlusOne. The company's mission is to enable the synthesis of pure and precise RNA for therapeutic use at an unprecedented scale, addressing the growing demand in the RNA therapeutics market, which includes siRNA, ASOs, mRNA, and CRISPR technologies.
EnPlusOne's innovative ezRNA platform leverages enzymatic synthesis to overcome the limitations of traditional phosphoramidite chemistry, offering a sustainable, precise, and scalable solution for RNA manufacturing. This breakthrough not only promises to enhance the production of current RNA therapeutics but also opens new avenues for discovering innovative RNA-based treatments. With upcoming milestones including operational scaling, synthesis efficiency improvements, and strategic partnerships, EnPlusOne is poised to lead the next wave of advancements in RNA therapeutics, ensuring broader patient access to these life-changing medicines.
Source Statement
This curated news summary relied on content disributed by citybiz. Read the original source here, EnPlusOne Biosciences CEO Clare Murray Ph.D. Pioneers Enzymatic RNA Synthesis
